ACST News and Press, Acasti Pharma Inc. From 11/13/19

November 13, 2019 Palm Beach, FL –November 13, 2019 – For decades researchers have been trying to find newer and more effective ways to fight cancer cells. Today much research is focused on attacking the cancerous cells growth. The reasoning is that denying these cells e...

Acasti Pharma (NASDAQ: ACST ): Q2 GAAP EPS of -$0.34 misses by $0.25 . More news on: Acasti Pharma Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

LAVAL, Québec, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre ...

Penny Stocks To Watch Right Now; But Are They Buy or Sell? If you are new to trading stocks, you may be unaware of what penny stocks are. According to the SEC, a penny stock is any equity that is trading below $5. This is important to know because if you have a smaller portfolio size, tra...

Craft Brew Alliance (NASDAQ: BREW ) +122%  on buyout . More news on: Craft Brew Alliance, Inc., Kadmon Holdings, Inc., Ladenburg Thalmann Financial Services Inc., Stocks on the move, Read more ...

LAVAL, Québec, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre ...

LAVAL, Quebec, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre&...

LAVAL, Québec, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti or the “Company”) (NASDAQ: ACST – TSX-V: ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre ...

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a bumpy week last week but, in the end, still had an increase from 3,122.33 points on Monday’s (October 7) open to reach 3,152.35 points as of 1:19 p.m. EDT on Friday (October 11). In terms of top performing stocks, a number of sm...

Branded Therapeutics: Vascepa Therapeutically, Vascepa launched in 2013 by Amarin ( AMRN ) is the current market leader over Lovaza launched in 2005 by GlaxoSmithKline ( GSK ). Epanova from AstraZeneca ( AZN ) was approved by the FDA in 2014. However, prior to its launch in 2014, Ama...